Rein Therapeutics Inc (RNTX) - Total Assets
Based on the latest financial reports, Rein Therapeutics Inc (RNTX) holds total assets worth $26.29 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rein Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Rein Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see RNTX market cap for the company's overall valuation and market capitalisation.
Rein Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Rein Therapeutics Inc's total assets of $26.29 Million consist of 17.9% current assets and 82.1% non-current assets. Review total liabilities of Rein Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.50 Million | 55.9% |
| Goodwill | $6.33 Million | 26.2% |
Asset Composition Trend (2015–2025)
This chart illustrates how Rein Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Rein Therapeutics Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rein Therapeutics Inc's current assets represent 17.9% of total assets in 2025, a decrease from 67.8% in 2015.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 63.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 55.9% of total assets.
Rein Therapeutics Inc Competitors by Total Assets
Key competitors of Rein Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Rein Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.40 | 1.39 | 14.08 |
| Quick Ratio | 0.40 | 1.39 | 14.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.18 Million | $2.35 Million | $55.88 Million |
Rein Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Rein Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.17 |
| Latest Market Cap to Assets Ratio | 2.79 |
| Asset Growth Rate (YoY) | -65.1% |
| Total Assets | $24.16 Million |
| Market Capitalization | $67.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Rein Therapeutics Inc's assets at a significant premium (2.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Rein Therapeutics Inc's assets decreased by 65.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rein Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Rein Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.16 Million | -65.11% |
| 2024-12-31 | $69.24 Million | -34.68% |
| 2023-12-31 | $106.01 Million | +381.70% |
| 2022-12-31 | $22.01 Million | -54.61% |
| 2021-12-31 | $48.48 Million | +196.68% |
| 2020-12-31 | $16.34 Million | -38.27% |
| 2019-12-31 | $26.47 Million | -12.66% |
| 2018-12-31 | $30.31 Million | -42.47% |
| 2017-12-31 | $52.69 Million | +139.26% |
| 2016-12-31 | $22.02 Million | +270.72% |
| 2015-12-31 | $5.94 Million | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more